Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
Dispatch

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands

Mirjam J. KnolComments to Author , Gertjan H.J. Wagenvoort, Elisabeth A.M. Sanders, Karin Elberse, Bart J. Vlaminckx, Hester E. de Melker, and Arie van der Ende
Author affiliations: National Institute for Public Health and the Environment, Bilthoven, the Netherlands (M.J. Knol, E.A.M. Sanders, K. Elberse, H.E. de Melker); St. Antonius Hospital, Nieuwegein, the Netherlands (G.H.J. Wagenvoort, B.J. Vlaminckx); University Medical Center Utrecht, Utrecht, the Netherlands (E.A.M. Sanders); Amsterdam Medical Center, Amsterdam, the Netherlands (A. van der Ende); Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam (A. van der Ende)

Main Article

Table 2

Number of IPD cases and incidence rate ratios determined on the basis of nationwide surveillance data, the Netherlands*

Variable PCV7-eligible cohort PCV10-eligible cohort IRR (95% CI)† Exact p value p value for interaction‡
Birth cohort 2008 Mar 1–2011 Feb 28 2011 Mar 1–2014 Feb 28 NA NA NA
Observation period 2008 Jun 1–2011 May 31 2011 Jun 1–2014 May 31 NA NA NA
Persons at risk 550,297 537,071 NA NA NA
Person-years at risk
 822,100
 814,980
 NA
 NA
 NA
No. (%) IPD cases per 100,000 persons
Serotypes
PCV7§ 5 (0.6) 0 (0.0) NC 0.063 NC
6B 2 0 NC NC NC
18C 2 0 NC NC NC
19F 1 0 NC NC NC
PCV10–7 27 (3.3) 1 (0.1) 0.04 (0.01–0.27) <0.001 0.005
1 2 0 NC NC NC
5 2 0 NC NC NC
7F 23 1 0.04 (0.01–0.32) <0.001 0.009
PCV10-related§ 33 (4.0) 14 (1.7) 0.43 (0.23–0.80) 0.006 0.229
6A 2 0 NC NC NC
6C 0 1 NC NC NC
9N 0 1 NC NC NC
19A 29 11 0.38 (0.19–0.77) 0.005 0.165
23A 1 1 NC NC NC
23B 1 0 NC NC NC
PCV10-unrelated 63 (7.7) 42 (5.2) 0.67 (0.46–0.99) 0.045 Reference
3 4 0 NC NC NC
8 3 2 NC NC NC
10A 14 16 NC NC NC
11A 3 0 NC NC NC
12F 2 2 NC NC NC
15A 1 0 NC NC NC
15B 3 1 NC NC NC
15C 1 4 NC NC NC
16F 4 1 NC NC NC
17F 3 1 NC NC NC
22F 5 3 NC NC NC
24B 0 1 NC NC NC
24F 3 1 NC NC NC
27 2 1 NC NC NC
33F 11 6 NC NC NC
34 1 0 NC NC NC
35B 0 1 NC NC NC
35F 2 1 NC NC NC
38
 1
 1
 NC
 NC
 NC
Total 128 (15.6) 57 (7.0) 0.45 (0.33–0.61) <0.001 NA

*IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conjugate vaccine; PCV10−7, serotypes present in PCV10 but not PCV7 (3 additional serotypes); PCV10, 10-valent pneumococcal conjugate vaccine; IRR, incidence rate ratio; NA, not applicable; NC, not calculated (numbers too low to be informative or relevant).
†PCV10-eligible cohort vs. PCV7-eligible cohort.
‡For difference between IRRs.
§serotypes with no IPD cases in both cohorts are not shown.

Main Article

Page created: November 03, 2015
Page updated: November 03, 2015
Page reviewed: November 03, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external